SMARTKEM, INC. ANNOUNCES 1-for-35 REVERSE STOCK SPLIT
MANCHESTER, England, Sept. 19, 2023
MANCHESTER, England, Sept. 19, 2023 /PRNewswire/ -- SmartKem, Inc. ("SmartKem" or the "Company") (OTCQB: SMTK), a company seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that will drive the next generation of displays, has announced that it will proceed with a 1-for-35 reverse stock split of its outstanding shares of common stock. The reverse stock split will become effective at 12:01 a.m. Eastern Time, on September 20, 2023.
The Company's common stock will begin trading on a post-split basis at the market open at 9:30 a.m., under the Company's existing trading symbol "SMTK". The CUSIP number for the common stock following the reverse stock split will be 83193D203.
SmartKem's OTCQB information can be found on the OTC Markets website: www.otcmarkets.com/stock/SMTK/overview
SmartKem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that can drive the next generation of displays. SmartKem's unique and patented TRUFLEX® semiconductor and dielectric inks, or liquid electronic polymers, are used to make a new type of transistor that has the potential to revolutionize the display industry. SmartKem's inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing models. The company's electronic polymer platform can be used in a number of display technologies including microLED, miniLED and AMOLED displays for next generation televisions, laptops, augmented reality (AR) and virtual reality (VR) headsets, smartwatches and smartphones.
SmartKem develops its materials at its research and development facility in Manchester, UK, its semiconductor manufacturing processes at the Centre for Process Innovation (CPI) at Sedgefield, UK and retains a field application office in Taiwan. The company has an extensive IP portfolio including 125 granted patents across 19 patent families and 40 codified trade secrets. For more information, visit: www.smartkem.com and follow us on LinkedIn and Twitter @SmartKemTRUFLEX.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the SmartKem's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on SmartKem Inc.'s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or elated expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- GigaCloud Technology Inc Responds to Short-Seller Report
- Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
- Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
- Traders Can Finally Experience the Power of AI with Arbitrix Edge's Automated Trading Platform
- BlackRock Greater Europe Investment Trust Plc - Mandatory Closed Period Compliance with MAR
- New number of votes in AB Volvo